A case of generalized bullous fixed drug eruptions induced by ceftriaxone
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20242437Keywords:
Generalized bullous fixed drug eruption (GBFDE), Ceftriaxone-induced hypersensitivity, Chronic Kidney Disease (CKD), Erythematous patches, Bullae and erosionsAbstract
Fixed drug eruption (FDE) is a delayed-type hypersensitivity reaction to a systemic medication. Generalized bullous fixed drug eruption (GBFDE) is a rare variant involving generalized bullae and erosions across multiple anatomical sites. A 66-year-old female with dialysis-dependent chronic kidney disease presented with fever and chills, and subsequently developed multiple erythematous to bluish annular nodules with central bullae on the hands, feet, tongue, buccal mucosa, and lips after ceftriaxone administration. Clinical examination revealed no prior history of drug allergies. Diagnostic assessments showed elevated serum creatinine and other parameters consistent with renal impairment. The suspected drug was discontinued, and patient treated with oral prednisolone, levocetirizine, topical betamethasone, and fusidic acid. Oral paste and gargles were prescribed for mucosal involvement. This case highlights the importance of recognizing ceftriaxone-induced GBFDE, particularly in patients with chronic kidney disease on haemodialysis. Prompt identification and cessation of the offending drug, along with appropriate therapeutic interventions, are critical for preventing future episodes and ensuring patient safety.
Metrics
References
Mitre V, Applebaum DS, Albahrani Y, Hsu S. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review. Dermatol Online J. 2017;23(7):1.
Manikandan R, Porselvi A, Keerthana GC, Vaishnavi K, Girija S, Narasimhan M, et al. Cefotaxime induced generalized bullous fixed drug eruption-a case report. Toxicol Reports. 2018;5:1011-3.
Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, et al. Generalized bullous fixed drug eruption differs from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539-48.
Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. Drugs. 1984;27(6):469-527.
Lee CH, Chen YC, Cho YT, Chang CY, Chu CY. Fixed-drug eruption: A retrospective study in a single referral center in northern Taiwan. Dermatological Sin. 2012;30(1):11-5.
Patel RD, Dosi R V, Shah PC, Joshi HS. Widespread bullous fixed drug eruption. BMJ Case Rep. BMJ Case Rep. 2014;2014:200584.
Kavoussi H, Rezaei M, Derakhshandeh K, Moradi A, Ebrahimi A, Rashidian H, et al. Clinical features and drug characteristics of patients with generalized fixed drug eruption in the West of Iran (2005-2014). Dermatol Res Pract. 2015;236:703.
Jain VK, Dixit VB, Archana. Fixed drug eruption of the oral mucous membrane. Ann Dent. 1991;50(1):9-11.